Arimidex from day 1?

[BloodyBillAnderson]

my first cycle was very mild, 10 weeks, sust 250 1 ml per week and 200mg deca on week 1 and week 5. I experienced some minor nipple sensitivity, not much but it was definitely a change from normal. pct was hcg and clomid. I am assuming it was gyno. is it unusual to have these symptoms with such a small amount of gear?

I am about to start my second cycle, consisting of 600 mg test cyp and 400 mg deca. I have some Arimidex on hand, would it be wise to use it from day 1? or should I wait for symptoms?



Thanks

[Flex-Appeal]

its preference butttttt most advise that you take it from the beginning @ .25mg ed.
a few say .5 but .25 should be fine

[magic32]

With such a foreboding history I'd recommend a much more aggressive protocol, namely the administration of Letro at .25mgs ED (adjusted accordingly if necessary), began at least two weeks prior to cycle as steady-state variance is rather wide but can in fact be achieved in a fortnight, and continued throughout PCT. For more on Letro and its properties see the Novartis' “Prescribing Information” (http://www.pharma.us.novartis.com/pr...pdf/Femara.pdf).

Note: Although often considered a secondary approach, should one have or develop complications with Letro, or find it inaccessible, then Nolva may be substituted at 20mgs ED following the same protocol mandates. However, for various reasons, there are many who believe that this therapy should not be instituted during cycles containing 19-Nors..I am not among them! I've witnessed it quite effectively arrest, reduce, and resolve gyno even in such cycles. It should also be noted that the primary reason for medicinal failure in gyno treatment is insufficient overall duration. To avoid recidivism these therapies should be administered for at least 3mths even in cases where the symptoms have subsided. Think of it like antibiotic instructions in which the doc directs you to use the whole bottle regardless.

I’ve also seen clinical studies in which PERSISTENT (far longer than usual) pubertal gyno was successfully resolved and sustained throughout follow-up with proper medicinal protocol:

TAMOXIFEN TREATMENT FOR PUBERTAL GYNECOMASTIA

We evaluated the efficacy of the tamoxifen treatment in 37 patients with pubertal gynecomastia. All had distinct, easily palpable breast swellings with a diameter of over three cm. Pain, tenderness, and swelling associated with gynecomastia were reported by six patients. Eight of the patients were obese. One patient also suffered from varicocele. Pain and size reduction was seen in all patients with tamoxifen treatment. No long-term side effects of tamoxifen were observed. The dose of tamoxifen was increased in three patients due to poor response. Two of the treatment group had recurrence problem at follow-up. We did not need to refer any patient to surgery. Tamoxifen treatment is relatively non-toxic, may be beneficial and we think it should be considered for pubertal gynecomastia.

Derman O, Kanbur NO, Kutluk T.
Section of Adolescent Medicine, Department of Pediatrics,
Hacettepe University Faculty of Medicine, 06100 Ankara-Turkey.

TREATMENT OF PERSISTENT PUBERTAL GYNECOMASTIA WITH DIHYDROTESTOSTERONE HEPTANOATE

Four boys with persistent pubertal gynecomastia were given intramuscular dihydrotestosterone heptanoate (DHT-hp) at 2 to 4-week intervals for 16 weeks. By the end of treatment, breast size in all four boys had decreased 67% to 78%. Initial plasma levels of gonadotropins, estradiol, testosterone, and dihydrotestosterone (DHT) were normal. Mean plasma DHT concentration rose with the injections of DHT-hp, and remained elevated throughout the treatment period. Estradiol, LH, FSH, and testosterone decreased during treatment, as did 24-hour urinary LH and FSH. No regrowth of breast tissue was observed 6 to 15 months after treatment, although hormone concentrations had returned to near pretreatment values by 2 months after the last injection. DHT-hp has potential to be an effective medical therapy for persistent pubertal gynecomastia.

Eberle AJ; Sparrow JT; Keenan BS
J Pediatr 1986 Jul;109(1):144-9.

BENEFICIAL EFFECTS OF RALOXIFENE AND TAMOXIFEN IN THE TREATMENT OF PUBERTAL GYNECOMASTIA.

OBJECTIVES: To assess the efficacy of the anti-estrogens tamoxifen and raloxifen in the medical management of persistent pubertal gynecomastia. STUDY DESIGN: Retrospective chart review of 38 consecutive patients with persistent pubertal gynecomastia who presented to a pediatric endocrinology clinic. Patients received reassurance alone or a 3- to 9-month course of an estrogen receptor modifier (tamoxifen or raloxifene). RESULTS: Mean (SD) age of treated subjects was 14.6 (1.5) years with gynecomastia duration of 28.3 (16.4) months. Mean reduction in breast nodule diameter was 2.1 cm (95% CI 1.7, 2.7, P <.0001) after treatment with tamoxifen and 2.5 cm (95% CI 1.7, 3.3, P <.0001) with raloxifene. Some improvement was seen in 86% of patients receiving tamoxifen and in 91% receiving raloxifene, but a greater proportion had a significant decrease (>50%) with raloxifene (86%) than tamoxifen (41%). No side effects were seen in any patients. CONCLUSION: Inhibition of estrogen receptor action in the breast appears to be safe and effective in reducing persistent pubertal gynecomastia, with a better response to raloxifene than to tamoxifen. Further study is required to determine that this is truly a treatment effect.

Lawrence SE; Faught KA; Vethamuthu J; Lawson ML
J Pediatr. 2004 Jul;145(1):71-6.

GIVE YOUR THERAPY A FIGHTING CHANCE!!!

[Drummerboy]

wow. thats a hell of an in depth answer.

[PT]

wow. thats a hell of an in depth answer.

e when majic or red barron post its always lie that. he has don some writing here and is an extremly intellegent person as is RB and everyone should pay very close attention to all there threads because you can learn a ton from the 2 of them.

[BloodyBillAnderson]

thanks, just ordered letro